@entity8 in XXXX .

@entity1 @entity8 @entity82 @entity3182 @entity810 @entity1011
PURPOSE OF REVIEW: @entity8 causes significant morbidity in cirrhotic @entity1 . Diagnosis is challenging because it is based on serum @entity1011 , which is used to calculate estimated glomerular filtration rate, which itself is not an ideal measure of renal function in @entity1 with @entity82 . Finding the exact cause of @entity8 in @entity1 with @entity82 remains problematic due to the limitations of the current diagnostic tests. The purpose of this review is to highlight studies used to diagnose @entity8 in @entity1 with @entity8 and review current treatments. RECENT FINDINGS: New diagnostic criteria and classification of @entity8 , especially for @entity810 ( @entity810 ), have been proposed in hopes of optimizing treatment and improving outcomes. New biomarkers that help to differentiate structural from functional @entity810 in cirrhotic @entity1 have been developed, but require further investigation. Vasoconstrictors are the most commonly recommended treatment of @entity3182 ( @entity3182 ). Given the high mortality in @entity1 with type 1 @entity3182 , all @entity1 with @entity3182 should be evaluated for liver transplantation. When @entity8 is considered irreversible, combined liver-kidney transplantation is advised. SUMMARY: Development of new biomarkers to differentiate the different types of @entity810 in @entity82 holds promise. Early intervention in cirrhotic @entity1 with @entity8 offers the best hope of improving outcomes.
